Ray T L, Payne C D
Marshall Dermatology Research Laboratories, Department of Dermatology, University of Iowa College of Medicine, Iowa City 52242.
Infect Immun. 1990 Feb;58(2):508-14. doi: 10.1128/iai.58.2.508-514.1990.
Six Candida spp. that were previously characterized for cutaneous pathogenicity were assessed for Candida acid proteinase (CAP) production in albumin-supplemented, nitrogen-restricted media. C. albicans CAP production was compared in media supplemented with albumin, casein, collagen, hemoglobin, or keratin and in TC medium 199. C. albicans, C. stellatoidea, and C. tropicalis, which are cutaneous pathogens in murine infections, produced 3.3 to 4.7 times more CAP than did the nonpathogens C. parapsilosis and C. guilliermondii. C. krusei, a nonpathogen, produced negligible amounts of enzyme. C. albicans CAP production was similar in each protein-supplemented medium, and only a single acid proteinase was recovered from each one. Rapid CAP purification from culture supernatants was achieved by hollow fiber and stirred cell ultrafiltration followed by Affi-Gel blue and Sephacryl column chromatographies. The highest yield, purity, and specific activity of CAP were obtained from keratin-supplemented medium supernatants, producing 2.86 mg of purified CAP from a 7-liter culture. CAP was characterized as a 41,500-dalton glycoprotein, with a pI of 4.5; a pH range of 2.5 to 5.5; and broad substrate specificity, including that for keratin, denatured collagen, hemoglobin, casein, and albumin. Isolation of CAP also isolated the keratinolytic proteinase of Candida spp. CAP was inhibited by pepstatin A, but not by EDTA or phenylmethylsulfonyl fluoride. Monospecific antibody to CAP was produced in mice and reacted only to the 41,500-dalton protein, as determined by immunoblot analysis. High CAP production by cutaneous pathogenic Candida spp. supports the fact that CAP is a potential virulence factor that may facilitate Candida colonization and invasion of skin. CAP production from keratin-supplemented medium was superior to that from the other media that were tested and yielded sufficient and suitable enzyme for use in immunoassays of CAP antigen and antibody.
对先前已鉴定具有皮肤致病性的6种念珠菌属菌株,在添加白蛋白、氮受限的培养基中评估其产念珠菌酸性蛋白酶(CAP)的情况。在添加白蛋白、酪蛋白、胶原蛋白、血红蛋白或角蛋白的培养基以及TC 199培养基中比较白色念珠菌的CAP产量。在鼠类感染中作为皮肤病原体的白色念珠菌、星状念珠菌和热带念珠菌产生的CAP比非病原体近平滑念珠菌和季也蒙念珠菌多3.3至4.7倍。非病原体克鲁斯念珠菌产生的酶量可忽略不计。白色念珠菌在每种添加蛋白质的培养基中的CAP产量相似,且每种培养基仅回收一种酸性蛋白酶。通过中空纤维和搅拌细胞超滤,随后进行Affi - Gel蓝和Sephacryl柱色谱法,可从培养上清液中快速纯化CAP。从添加角蛋白的培养基上清液中获得的CAP产量、纯度和比活性最高,7升培养物可产生2.86毫克纯化的CAP。CAP被鉴定为一种41,500道尔顿的糖蛋白,pI为4.5;pH范围为2.5至5.5;底物特异性广泛,包括对角蛋白、变性胶原蛋白、血红蛋白、酪蛋白和白蛋白的特异性。CAP的分离还分离出了念珠菌属的角蛋白分解蛋白酶。CAP被胃蛋白酶抑制剂A抑制,但不被EDTA或苯甲基磺酰氟抑制。在小鼠中产生了针对CAP的单特异性抗体,经免疫印迹分析确定,该抗体仅与41,500道尔顿的蛋白质发生反应。皮肤致病性念珠菌属菌株的高CAP产量支持了CAP是一种潜在毒力因子的事实,它可能有助于念珠菌在皮肤的定植和侵袭。从添加角蛋白的培养基中产生的CAP优于所测试的其他培养基,产生了足够且适合用于CAP抗原和抗体免疫测定的酶。